Skip to main content

Table 4 Efficacy of first-line anti-malarials in three therapeutic efficacy monitoring sites in Angola, 2015

From: Efficacy of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015

  Efficacy (95% confidence intervals)
Benguela Zaire Lunda Sul
ASAQa ALa ALa DPb DPb ASAQa
Uncorrected
 Per-protocol Day 28 90.4 (81–96) 89.4 (80–95) 75.3 (65–83) 95.6 (88–99) 100 (94–100) 100 (92–100)
 Per-protocol Day 42 81.9 (72–89) 100 (94–100)
 Kaplan–Meier estimate Day 28 90.3 (84–97) 89.6 (83–96) 76.0 (68–85) 95.5 (91–100) 100 100
 Kaplan–Meier estimate Day 42 82.5 (75–91) 100
PCR-corrected
 Per-protocol Day 28 99.9 (95–100) 96.1 (89–99) 86.5 (77–92) 98.8 (94–99) 100 (96–100) 100 (94–100)
 Per-protocol Day 42 98.5 (92–99) 100 (96–100)
 Kaplan–Meier estimate Day 28 99.9 (95–100) 96.3 (91–100) 88.1 (81–95) 98.8 (96–100) 100 100
 Kaplan–Meier estimate Day 42 98.8 (96–100) 100
  1. Per-protocol efficacy defined as proportion adequate clinical and parasitological response (ACPR), Kaplan–Meier estimate calculated from estimate of survival function
  2. ASAQ artesunate–amodiaquine, AL artemether–lumefantrine, DP dihydroartemisinin–piperaquine
  3. a28-day follow up
  4. b42-day follow up